Communication

News

GIO Therapeutics – nouveau membre international

26 February 2024
New member

GIO Therapeutics stands at the forefront of medical innovation, specialising in the development of G protein-coupled receptor (GPCR)-targeted pharmaceuticals. Our innovative approach positions us to address complex challenges in oncology and inflammatory diseases. Our focus is not only to discover; our aim is to significantly improve patient outcomes. This bold vision, together with our commitment to groundbreaking research, makes GIO Therapeutics a leader in the field. Our strategic approach to drug development positions us as a compelling opportunity in a rapidly evolving field. To know more